

October 5, 2021

Via EDGAR

U.S. Securities and Exchange Commission  
Division of Corporation Finance  
100 F Street, N.E.  
Washington, D.C. 20549-3720

Attention: Tim Buchmiller  
Jeffrey Gabor  
Kristin Lochhead  
Vanessa Robertson

Re: Pyxis Oncology, Inc.  
Registration Statement on Form S-1  
File No. 333-259627

**Acceleration Request**

**Requested Date: October 7, 2021**

**Requested Time: 4:00 P.M., Eastern Time**

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Pyxis Oncology, Inc. (the "**Company**"), hereby requests that the effective date of the Company's Registration Statement on Form S-1, Registration Number 333-259627 (the "**Registration Statement**") be accelerated so that the Company's Registration Statement will become effective at 4:00 P.M., Eastern Time, on October 7, 2021, or as soon thereafter as practicable or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the U.S. Securities and Exchange Commission.

We would appreciate it if, as soon as the Registration Statement is declared effective, you would so inform Istvan Hajdu of Sidley Austin LLP at (212) 839-5651.

---

Very truly yours,

/s/ Lara Sullivan

---

Lara Sullivan, M.D.  
Chief Executive Officer  
Pyxis Oncology, Inc.

cc: Pamela Connealy, Pyxis Oncology, Inc.  
Frank Rahmani, Sidley Austin LLP  
Asher Rubin, Sidley Austin LLP  
Istvan Hajdu, Sidley Austin LLP  
Nathan Ajiashvili, Latham & Watkins LLP